Cargando…
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
BACKGROUND: Loss of function of triggering receptor expressed on myeloid cell 2 (TREM2), a key receptor selectively expressed by microglia in the brain, contributes to the development of Alzheimer’s disease (AD). Whether TREM2 levels are pathologically altered during the preclinical phase, and wheth...
Autores principales: | Ma, Ling-Zhi, Tan, Lan, Bi, Yan-Lin, Shen, Xue-Ning, Xu, Wei, Ma, Ya-Hui, Li, Hong-Qi, Dong, Qiang, Yu, Jin-Tai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149923/ https://www.ncbi.nlm.nih.gov/pubmed/32276587 http://dx.doi.org/10.1186/s13024-020-00374-8 |
Ejemplares similares
-
sTREM2 mediates the associations of minimal depressive symptoms with amyloid pathology in prodromal Alzheimer’s disease: The CABLE study
por: Wang, Zhi-Bo, et al.
Publicado: (2022) -
Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study
por: Li, Meng, et al.
Publicado: (2022) -
Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023) -
CSF sTREM2: marking the tipping point between preclinical AD and dementia?
por: Schindler, Suzanne E, et al.
Publicado: (2016) -
Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer’s disease
por: Wang, Zhi-Bo, et al.
Publicado: (2022)